MFAR Clinical Research S.L.
MFAR Clinical Research S.L.
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 2 | 2026-10-02 | NCT07394153 | |
| Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Fanconi anemia, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Nutritional and Metabolic Diseases, anemia, aplastic anemia, bone marrow disorder, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, hematologic disorder, hereditary disease, inherited aplastic anemia, metabolic disease, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-05-27 | NCT06648096 | |
| Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients | Mibc; Muscle Invasive Bladder Cancer | Not yet recruiting | Phase 2 | 2024-10-04 | NCT06623162 |